Osimertinib: beside a new treatment under test
105 studies: a new drug, cell therapy or vaccine is what the study tests. Page 1 of 2. Open to participants first (45), then studies with results posted, then the rest; newest registration first within each.
- A Phase 2 Study of ABSK043 Combined With OsimertinibNot yet recruitingNCT07710612Phase 2How we knowReport a problem
- Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)RecruitingNCT07680790Phase 3How we knowReport a problem
- A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung CancerRecruitingNCT07669779Phase 2How we knowReport a problem
- A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)RecruitingNCT07642024Phase 2/3How we knowReport a problem
- A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)RecruitingNCT07640789Phase 3How we knowReport a problem
- A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT07622186Phase 2How we knowReport a problem
- Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid TumorsNot yet recruitingNCT07612137Phase 1/2How we knowReport a problem
- Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants.Not yet recruitingNCT07603791Phase 2How we knowReport a problem
- A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung CancerRecruitingNCT07535437Phase 1/2How we knowReport a problem
- A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLCNot yet recruitingNCT07376382Phase 3How we knowReport a problem
- A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib MonotherapyRecruitingNCT07375316Phase 2How we knowReport a problem
- Zorifertinib With Osimertinib for NSCLC With Meningeal ProgressionRecruitingNCT07361705Phase 1How we knowReport a problem
- Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerRecruitingNCT07329322Phase 2How we knowReport a problem
- Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET AmplificationRecruitingNCT07322783Phase 2How we knowReport a problem
- Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung CancerRecruitingNCT07315113Phase 1How we knowReport a problem
- A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung CancerNot yet recruitingNCT07256509Phase 2How we knowReport a problem
- A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLCRecruitingNCT07206498Phase 1/2How we knowReport a problem
- A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerRecruitingNCT07155187Phase 2/3How we knowReport a problem
- A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLCNot yet recruitingNCT07038460Phase 2How we knowReport a problem
- A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerRecruitingNCT07005102Phase 2/3How we knowReport a problem
- Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer PatientsNot yet recruitingNCT06908772Phase 2/3How we knowReport a problem
- A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid TumorsRecruitingNCT06895928Phase 2How we knowReport a problem
- A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIsRecruitingNCT06829459Phase 3How we knowReport a problem
- A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive MutationsRecruitingNCT06735391Phase 3How we knowReport a problem
- A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver GenesRecruitingNCT06712680Phase 1/2How we knowReport a problem
- A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid TumorsRecruitingNCT06618287Phase 1/2How we knowReport a problem
- Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.Not yet recruitingNCT06452433Phase 2How we knowReport a problem
- JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins MutationsNot yet recruitingNCT06380348Phase 3How we knowReport a problem
- Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II TrialRecruitingNCT06363734Phase 2How we knowReport a problem
- A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR MutationsRecruitingNCT06362980Phase 1How we knowReport a problem
- Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung CancerRecruitingNCT06350097Phase 3How we knowReport a problem
- A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLCRecruitingNCT06306456Phase 1/2How we knowReport a problem
- RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 AlterationsNot yet recruitingNCT06185400Phase 2How we knowReport a problem
- The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLCRecruitingNCT06109558Phase 1/2How we knowReport a problem
- A Study of DB-1310 in Advanced/Metastatic Solid TumorsRecruitingNCT05785741Phase 1/2How we knowReport a problem
- EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung CancerNot yet recruitingNCT05498389Phase 1/2How we knowReport a problem
- VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung CancerRecruitingNCT05489731Phase 1How we knowReport a problem
- Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung CancerRecruitingNCT05401110Phase 1How we knowReport a problem
- Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung CancerRecruitingNCT05142189Phase 1How we knowReport a problem
- Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung CancerRecruitingNCT04780568Phase 1How we knowReport a problem
- Phase I Study of Repotrectinib and Osimertinib in NSCLC PatientsRecruitingNCT04772235Phase 1How we knowReport a problem
- MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung CancerRecruitingNCT04762199Phase 1How we knowReport a problem
- Study to Evaluate VT3989 in Patients With Metastatic Solid TumorsRecruitingNCT04665206Phase 1/2How we knowReport a problem
- Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on OsimertinibRecruitingNCT04486833Phase 1/2How we knowReport a problem
- Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Prospective StudyRecruitingNCT04401059Phase 4How we knowReport a problem
- Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLCCompletedNCT03989115Phase 1/2Results postedHow we knowReport a problem
- A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)CompletedNCT03940703Phase 2Results postedHow we knowReport a problem
- Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung CancerActive, not recruitingNCT03831932Phase 1/2Results postedHow we knowReport a problem
- Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior OsimertinibActive, not recruitingNCT03778229Phase 2Results postedHow we knowReport a problem
- G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung CancerCompletedNCT03455829Phase 1/2Results postedHow we knowReport a problem
- Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination StudyActive, not recruitingNCT03381274Phase 1/2Results postedHow we knowReport a problem
- DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung CancerTerminatedNCT03255083Phase 1Results postedHow we knowReport a problem
- An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung CancerCompletedNCT07271446Phase 1How we knowReport a problem
- A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)Active, not recruitingNCT06838273Phase 3How we knowReport a problem
- Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLCActive, not recruitingNCT06827145Phase 2How we knowReport a problem
- A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerActive, not recruitingNCT06670196Phase 3How we knowReport a problem
- Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung CancerCompletedNCT06525246Phase 1How we knowReport a problem
- A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid MalignanciesActive, not recruitingNCT06507306Phase 1How we knowReport a problem
- A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerActive, not recruitingNCT06498986Phase 2How we knowReport a problem
- A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT06417814Phase 3How we knowReport a problem
- JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common MutationsActive, not recruitingNCT06391944Phase 2How we knowReport a problem
- Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met ProteinWithdrawnNCT06093503Phase 3How we knowReport a problem
- BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR MutationsTerminatedNCT06032936Phase 1How we knowReport a problem
- Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal CancerCompletedNCT05954871Phase 1How we knowReport a problem
- A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerActive, not recruitingNCT05880706Phase 2How we knowReport a problem
- A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)Active, not recruitingNCT05816252Phase 2How we knowReport a problem
- Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung CancerWithdrawnNCT05693090Phase 1How we knowReport a problem
- First in Human Study of AZD9592 in Solid TumorsActive, not recruitingNCT05647122Phase 1How we knowReport a problem
- TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung CancerStatus unknownNCT05284994Phase 1/2How we knowReport a problem
- Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib TreatmentActive, not recruitingNCT05261399Phase 3How we knowReport a problem
- Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid TumorsTerminatedNCT05228015Phase 1How we knowReport a problem
- Personalized DC Vaccines in Non Small Cell Lung CancerActive, not recruitingNCT05195619Phase 1How we knowReport a problem
- Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung CancerActive, not recruitingNCT05166616Phase 1How we knowReport a problem
- Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLCActive, not recruitingNCT05163249Phase 2How we knowReport a problem
- (HARMONY) Study of BLU-701 in EGFR-mutant NSCLCTerminatedNCT05153408Phase 1How we knowReport a problem
- Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung CancerStatus unknownNCT05132777Phase 2How we knowReport a problem
- SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.Active, not recruitingNCT05020769Phase 2/3How we knowReport a problem
- Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung CancerCompletedNCT05017025Phase 1/2How we knowReport a problem
- Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET AmplificationCompletedNCT05015608Phase 3How we knowReport a problem
- Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLCActive, not recruitingNCT05009836Phase 3How we knowReport a problem
- A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLCCompletedNCT04959981Phase 1How we knowReport a problem
- Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in CombinationTerminatedNCT04868877Phase 1/2How we knowReport a problem
- (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLCTerminatedNCT04862780Phase 1How we knowReport a problem
- Advanced Lung Tumor Treated by Osimertinib Plus AnlotinibCompletedNCT04770688Phase 1/2How we knowReport a problem
- Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT04743505Phase 1/2How we knowReport a problem
- Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid TumorsActive, not recruitingNCT04721015Phase 1How we knowReport a problem
- JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid TumorsCompletedNCT04720976Phase 1/2How we knowReport a problem
- HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung CancerActive, not recruitingNCT04676477Phase 1How we knowReport a problem
- Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung CancerCompletedNCT04479306Phase 1How we knowReport a problem
- Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung CancerStatus unknownNCT04448379Phase 1How we knowReport a problem
- Osimertinib Combined With Anlotinib in EGFR T790M Mutated NSCLC Patients With Progression on Osimertinib TreatmentTerminatedNCT04438902Phase 2How we knowReport a problem
- Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal MetastasisStatus unknownNCT04356118Phase 4How we knowReport a problem
- Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR InhibitorsStatus unknownNCT04338243Phase 1/2How we knowReport a problem
- Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung CancerCompletedNCT04085315Phase 1How we knowReport a problem
- Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790MStatus unknownNCT04029350Phase 2How we knowReport a problem
- A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC PatientsCompletedNCT04001777Phase 1How we knowReport a problem
- Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung CancerCompletedNCT03450330Phase 1/2How we knowReport a problem
- MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLCTerminatedNCT03418532Phase 1How we knowReport a problem
- A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung CancerActive, not recruitingNCT03392246Phase 2How we knowReport a problem
- Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung CancerStatus unknownNCT03050411Phase 1How we knowReport a problem